Web11 dec. 2024 · Overall survival (OS) of multiple myeloma has improved remarkably over time, with the recent Intergroupe Francophone du Myelome (IFM) 2009 randomized trial reporting a 4-year OS rate of... Web1 mrt. 2024 · IFM2009 included 700 patients with MM who were randomized to receive induction therapy with RVD (lenalidomide, bortezomib, dexamethasone) with or without high-dose melphalan. All patients also received 12 months of lenalidomide as …
Health-related quality of life results from the IFM 2009 trial ...
Web8 dec. 2024 · Methods: The IFM2009 trial randomized 700 patients to received high-dose melphalan or not following a RVD induction. All the patients did then receive a 12-month lenalidomide maintenance. MRD was assessed before and after maintenance using the ClonoSeq kit (Adaptive Biotechnologies, Seattle, WA). Web3 jun. 2024 · The Intergroupe Francophone du Myélome and Dutch-Belgian Cooperative Trial Group for Hematology Oncology sponsored this trial and, with Janssen Research & Development, collaborated in its design. The sponsors compiled and maintained investigator-collected data. rocker revolving recliners with matchin sofas
Frontiers Minimal Residual Disease in Multiple Myeloma: Current ...
WebThe Intergroupe Francophone du Myelome 2009 trial (NCT01191060) assessed health-related quality of life (HRQoL) in patients with newly diagnosed multiple myeloma … Web15 dec. 2024 · Two- and 3-drug treatment regimens and autologous stem cell transplants provide opportunities for longer term disease remission, though most patients will still develop relapsed multiple myeloma. Web8 apr. 2024 · The final analysis of the IFM2009 prospective trial demonstrated the significance of MRD negativity, whereby patients achieving MRD negativity after induction with VRD had a similar OS... otc 4467